The purchase price of the shares was $17 per share. Genoptix sold a total of 4,735,714 shares in the offering, resulting in net proceeds of approximately $72.7 million after deducting the underwriting discounts and commission and the estimated offering expenses.
The offering is being made through an underwriting syndicate led by Lehman Brothers, acting as sole book-running manager. Banc of America Securities is acting as joint lead manager and Cowen and Company as co-manager.
Carlsbad, California-based Genoptix is a specialized laboratory service provider focused on delivering personalized and comprehensive diagnostic services to community-based hematologists and oncologists.